A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

Taoyuan District

Taichung

Manila

Metro Manila

Vienna

Quezon City

Budapest

Bruxelles - Brussel

Budapest

Sofia

Rosario

Antwerp

Törökbálint

Johannesburg

Genk

Edelény

Linz

Durban

Córdoba

Charleroi

Cebu City

Port Elizabeth

Cape Town

Graz

Farkasgyepű

Zalaegerszeg

Varna

Varna

Taipei

Orbassano

Bangkok

Jakarta

Athens

Caen

Genova

Philadelphia

Monza

Rozzano

Dijon

Hamburg

Großhansdorf

Lleida

Lugo

Madrid

Málaga

Ourense

Kassel

Instanbul

Tours

La Tronche

Bandung

Taichung

Seville

Kocaeli

Parma

Saint-Herblain

Cruces/Barakaldo

Zamora

Chiang Mai

Cologne

Lahore

Livorno

Lille

Mannheim

Heidelberg

Lyon

Fayetteville

Karachi

Karlsruhe

München

Kaohsiung City

Gauting

Avellino

La Roche-sur-Yon

Ulm

Songkhla

Stanford

Bad Berka

Beijing

Beijing

Beijing

Beijing

Moscow

Singapore

Moscow

Yaroslavl

Saint Petersburg

Shanghai

Shanghai

Nanjing

Singapore

Hangzhou

Hangzhou

Pune

Kazan'

Mumbai

Guangzhou

Guangzhou

Chengdu

Kerala

Kfar Saba

Petah Tikva

Zrifin

Jerusalem

Jerusalem

São José dos Campos

Ramos Mejía

Buenos Aires

Córdoba

Rosario

Santa Fé

Brasília

Belo Horizonte

Porto Alegre

Porto Alegre

Santo André

São Paulo

São Paulo

Plovdiv

Sofia

Shatin

Hong Kong

Kowloon

Holon

San Borja

Ankara

Istanbul

Izmir

Montreal

Santiago

Santiago

Heraklion

Thessaloniki

Perugia

Roma

Nagoya

Kashiwa

Fukuoka

Akashi

Sakai

Sayama

Itabashi-ku

Koto-ku

Amsterdam

Harderwijk

Heerlen

Helmond

Nieuwegein

Zwolle

Callao

Lima

Lima

Lima

Lima

Kielce

Krakow

Olsztyn

Rzeszów

Szczecin

Warsaw

Moscow

Prietoria

Seoul

Seoul

Seoul

Seoul

Seoul

Barcelona

Barcelona

Falun

Gothenburg

Linköping

Lund

Stockholm

Bristol

Cambridge

London

London

Greater Manchester

Sutton

Leeds

Aberdeen